Background: General opinion on pathogenesis and prevalence of bronchial asthma indicates that age and sex are the major risk factors. Detailed physiological mechanisms of the changing sex ratio are not fully known. Aims and objectives: Investigate the influence the asthmatic patients treated with anti-IgE with different gender. Methods: Here, we pooled data from ten published studies from 1999 with more of our unpublished data of patients with severe persistent asthma treated with omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody. Static analysis was used to find gender risk factors as the ratio of treatment effect (omalizumab: control) on the standardized exacerbation rate per year. Results: The studies included 3270 patients (treated with omalizumab), whose had severe persistent asthma according to the Global Initiative for Asthma (GINA) classification. Analysis of 2 groups male versus female showed that the efficacy of omalizumab on asthma exacerbations was unaffected by patient age, gender, baseline serum IgE (split by median) or by 2-or 4-weekly dosing schedule, although a more large number of women were treated (1921/1349; 59 % women vs 41% men; P , 0.001) and benefit in absolute terms appeared to be greatest in women patients which had a more severe asthma, defined by a lower value of percentage predicted forced expiratory volume in 1 second (FEV1) at baseline, this subgroup showed odds of being a responder (composite definition) 1.25 times higher (95% CI, 1.18-3.01) than men. Conclusions: These results suggest that in population of asthmatics treated with anti-IgE the number of women is shown higher than men, it confirms that asthma should be considered with different approach by the gender for being adequately controlled on current therapy.
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Fetal Loss in Severe Asthma and Posterior Healthy Pregnancy and Birth with the Use of OmalizumabdCase Report Fábio Kuschnir, PhD, 1 Fatima Emerson, MD, 2 Nelson Cordeiro, MD, 2 Michele Viegas Rocha, MD, 2 Silvio Lima Filho, MD, 2 and Jose Luiz Rios, MD 2 . 1 Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil; 2 Allergy, Policlinica Geral do Rio de Janeiro, Rio de Janeiro, Brazil. Background: Pregnancy may aggravate asthma and result in life-threatening for both mother and foetus. The humanized monoclonal antibody omalizumab has proven to be effective in controlling severe asthma. The purpose of this case report is to present the effectiveness and safety of this medicine during pregnancy. Methods: Case report of a severe asthmatic pregnant woman who had a previous foetal loss due to asthmatic exacerbation, and obtained a subsequent successful pregnancy and delivery with omalizumab use. Results: KRF, 35, female, housewife, presented bronchial asthma associated with allergic rhinosinusitis since childhood with periods of remission and exacerbations. Since 15 years old, she presented progressive worsening of the disease with increased intensity and frequency of the attacks. In 2005 she became pregnant, progressing with severe attacks, emergency visits and hospital admissions, and requiring courses of systemic corticosteroids, despite continued treatment including combined of long-acting beta agonist (LABA) and inhaled corticosteroids (IC), besides Montelucast and Bamiphylline. Nevertheless, the pregnancy was interrupted at 8 months, due to the fetal death. Despite using regularly Formoterol (24 mcg/day) and Ciclesonide (640 mcg/day), the exacerbations became frequent, requiring continuous oral prednisolone, 20 mg daily, to achieve asthma control. Other risk factors for severe asthma were ruled out through extensive investigation. Omalizumab, 300 mg monthly, was introduced in July 2006, resulting in important improvement of the asthma control, allowing the discontinuation of systemic corticosteroids in 2 months, and subsequent reduction of Ciclesonide and formoterol doses. Discontinuation in Omalizumab use resulted in asthma worsening, despite the increment in the other medications doses. When omalizumab administration was restored, 8 months later, the asthma control was achieved again. In November 2010, she became pregnant and the same treatment plan for asthma was maintained. Only one episode of a mild exacerbation of asthma occurred due to a respiratory infection. The pregnancy reached full-term with a cesarean section in May 2011 with mother and newborn presenting satisfactory health conditions. Conclusions: Omalizumab has shown efficacy and safety in the control of severe asthma during pregnancy, reducing the risk of injury to health for both mother and newborn.
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Vasculitic Urticaria Treated with Omalizumab. Case Report María Elena Ramírez Del Pozo, MD, Nancy Paola Martínez Saenz, MD, Javier Gomez Vera, MD, and Jesus Lopez Tiro, MD. Alergia e inmunologia, Hospital Regional "Lic. Adolfo López Mateos" ISSSTE, Distrito Federal, Mexico. Background: Vasculitic urticaria (UV) is a condition characterized by hives lasting more than 24 hours, itchy and burning with residual hyperpigmentation. Histopathology is characterized by leukocytoclastic vasculitis, perivascular infiltrate and fibrin deposits. The incidence is approximately 2%, prevalence in women (5:1). The treatment includes steroids, immunosuppressants, and has suggested the use of monoclonal antibodies. We report a patient treated with omalizumab. Methods: Female 51 years old, his mother died of complications from Lupus Erythematosus (SLE). 10 years ago was diagnosed with SLE by criteria haematological and immunological joints treated with azathioprine, chloroquine and deflazacort, with control of lupus, immunosuppressive suspended and continuing low-dose steroids. Have hives as secondary reaction to netilmicin and penicillin. Two years ago shows like lesions papules and burning and itching rash on chest and limbs, with no peeling hyperpigmented macules, managed with systemic steroids (prednisone) and antihistamines, with a decrease of the same but has l month after similar injuries, and macula, adjust the dose of steroid 1 mg/kg with a decrease in events with exacerbations and remissions, until 3 months course again with increasing symptoms with erythematous, violaceous, painful to the touch did not disappear in extremities lower, upper abdomen and chest, with no improvement after systemic steroids, antihistamines, and immunosuppressants, laboratories report 4.600 leukocytes, eosinophils 100/mcl, 90.1 mgU/dl C3, C4 8.6 mg/dL of 169 I U IgE/mL, leukocytoclastic vasculitis biopsy reports, deciding Omalizumab use was calculated based on weight and IgE, showing significant improvement with disappearance of the lesions, without pain or itching with hives. Results: Gradual decrease was observed of Score of 6 to 1 and score-related quality of of life with a 84.37 to 42.36 CUQ2oL after 3 applications, with a significant P by comparing the results and statistical analysis. Conclusions: We conclude that Omalizumab may be useful in the treatment of vasculitic urticaria, although it requires clinical trials that include a greater number of patients and be compared with conventional treatment.
